A PRACTICAL APPROACH TO ANTIBIOTIC-TREATMENT IN WOMEN TAKING ORAL-CONTRACEPTIVES
pharmacokinetics; pregnancy; tetracycline; Dermatology; estradiol; rifampicin; ampicillin; drug-interactions; enterohepatic circulation; norethisterone; norgestimate
Clinical situations that require the use of systemic antibiotic therapy are common. Because millions of women choose oral contraceptives for birth control, the potential for interaction between these drugs frequently has to be considered. We review the available information and present a practical approach for dealing with this situation based on sharing responsibility with an educated patient.
Miller D M; Helms S E; Brodell R T
Journal of the American Academy of Dermatology
1994
1994-06
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/s0190-9622(94)70127-x" target="_blank" rel="noreferrer noopener">10.1016/s0190-9622(94)70127-x</a>
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
COMMUNICABLE diseases; community-acquired bacterial pneumonia; COMMUNITY-acquired pneumonia; DENTAL discoloration; omadacycline; PATIENT safety; safety; skin and skin structure infections; SKIN diseases; TEETH abnormalities; TETRACYCLINE; THERAPEUTIC use
Omadacycline is a semisynthetic tetracycline antibiotic. Phase III clinical trial results have shown that omadacycline has an acceptable safety profile in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Similar to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotransferases were the most frequent treatment-emergent adverse events in phase III studies but were not treatment limiting. Package insert warnings and precautions for omadacycline include tooth discoloration; enamel hypoplasia; inhibition of bone growth following use in late pregnancy, infancy, or childhood up to 8 years of age; an imbalance in mortality (2%, compared with 1% in moxifloxacin-treated patients) was observed in the phase III study in patients with community-acquired bacterial pneumonia. Omadacycline has no effect on the QT interval, and its affinity for muscarinic M2 receptors resulted in transient heart rate increases following dosing.
Opal Steven; File Thomas M; van der Poll Tom; Tzanis Evan; Chitra Surya; McGovern Paul C
Clinical Infectious Diseases: An Official Publication Of The Infectious Diseases Society Of America
2019
2019-08
<a href="http://doi.org/10.1093/cid/ciz398" target="_blank" rel="noreferrer noopener">10.1093/cid/ciz398</a>
Minocycline-induced hyperpigmentation: comparison of 3 Q-switched lasers to reverse its effects.
antibiotic; discoloration; inflammatory disease; rheumatoid arthritis; tetracycline; wavelength
Minocycline is a tetracycline derivative antibiotic commonly prescribed for acne, rosacea, and other inflammatory skin disorders. Minocycline turns black when oxidized, leading to discoloration of the skin, nails, bulbar conjunctiva, oral mucosa, teeth, bones, and thyroid gland. Hyperpigmentation has been reported after long-term minocycline therapy with at least 100 mg/day. Three types of minocycline-induced cutaneous hyperpigmentation can result. Type I is the most common, and is associated with blue-black discoloration in areas of previous inflammation and scarring. Type II most commonly affects the legs and is characterized by blue-gray pigmentation of previously normal skin. Type III is the least common and is characterized by diffuse muddy-brown discoloration predominantly on sun exposed skin. Minocycline-induced hyperpigmentation may be cosmetically disfiguring and prompt identification is essential. Without treatment, symptoms may take several months, to years to resolve, after discontinuation of the drug. However, the pigmentation may never completely disappear. In fact, there have been few reports of complete resolution associated with any therapeutic intervention. We report a case of a patient on long-term minocycline therapy utilized as an anti-inflammatory agent to control symptoms of rheumatoid arthritis, which led to minocycline-induced hyperpigmentation of the face. To remove the blue-gray cutaneous deposits, 3 Q-switched lasers (Neodymium: yttrium aluminum garnet (Nd:YAG) 1064 nm, Alexandrite 755 nm, and Ruby 694 nm) were used in test areas. The Alexandrite 755 nm laser proved to provide effective clearing of the minocycline hyperpigmentation requiring just 2 treatments, with minimal treatment discomfort and down time.
Nisar Mahrukh S; Iyer Karthik; Brodell Robert T; Lloyd Jenifer R; Shin Thuzar M; Ahmad Asad
Clinical, cosmetic and investigational dermatology
2013
1905-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.2147/CCID.S42166" target="_blank" rel="noreferrer noopener">10.2147/CCID.S42166</a>